Semaglutide ‘shows promise’ for secondary CV prevention regardless of diabetes status
The trial included more than 17,000 patients with pre-existing cardiovascular disease and overweight or obesity.
Adding semaglutide to standard care cuts the risk of fatal and non-fatal cardiac events by 20% in adults with pre-existing cardiovascular disease but not diabetes, US-led doctors report.
Results from the Novo Nordisk–funded trial suggest the GLP-1 receptor agonist could be used for secondary cardiovascular prevention in those with overweight or obesity regardless of diabetes status.
